pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,539 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT814Endpoints614BioPharma Dive236onclive165Fierce Biotech81BioSpace79raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues United
    We've been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.
    STAT · 1mo ago↗ source
  • Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
    🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
    CHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...
    Endpoints
← prev
page 40 of 62
next →
21
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1mo ago
↗ source
  • After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
    Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
    Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
    STAT · 1mo ago↗ source
  • Opinion: What should hospitals do when patients demand unvaccinated donor blood?
    “You have to understand a person's belief if you want to address it,” Deva Sharma says on the “First Opinion Podcast” about requests for unvaccinated donor blood.
    STAT · 1mo ago↗ source
  • STAT+: A turning point for pancreatic cancer patients
    Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • CDC says containing the spread of Ebola is top priority
    The Trump administration disregards infectious disease playbook, CEPI offers vaccine funding, and other health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Turn Therapeutics' eczema drug shows rapid response in mid-stage data
    California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of…
    Endpoints · 1mo ago↗ source
  • Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
    Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…
    Endpoints · 1mo ago↗ source
  • STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
    The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
    STAT · 1mo ago↗ source
  • #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup
    CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Indiv…
    Endpoints · 1mo ago↗ source
  • Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
    Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront i…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
    CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with t…
    Endpoints · 1mo ago↗ source
  • Opinion: The military’s medical corps has a serious recruitment problem
    Congress must incentivize more physicians (and their employers) to join the military medical corps, writes the former attending physician to Congress.
    STAT · 1mo ago↗ source
  • Opinion: Medical schools diversified. So where are all the diverse doctors?
    Why are residency programs disciplining and dismissing trainees in a system funded to train them?
    STAT · 1mo ago↗ source
  • STAT+: Executives reveal tech initiatives at Summa Health, eight months after General Catalyst acquisition
    Two years after General Catalyst said it was buying Ohio safety-net hospital Summa Health, executives shed light on how the “transformation” is going.
    STAT · 1mo ago↗ source
  • STAT+: Medicare still won’t say how much covering obesity drugs will cost
    Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
    STAT · 1mo ago↗ source
  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    STAT · 1mo ago↗ source
  • STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
    The arbitration process has protected patients but generated financial windfalls for some clinicians.
    STAT · 1mo ago↗ source
  • Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
    Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS-0…
    Endpoints · 1mo ago↗ source
  • STAT+: A standing ovation for RevMed, and caution for Akeso
    ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
    STAT · 1mo ago↗ source
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    STAT · 1mo ago↗ source
  • #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that good
    CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News. “H…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
    CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…
    Endpoints · 1mo ago↗ source